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rates for HF (34%) is consistent with that generally reported in NYHA Class 11-111 systolic 
dvsfunction heart failure. 
1136-81 Evolution of Left Ventricular Filling Pattern Among 
American Indians: The Strong Heart Study 
Felizen S. Aano, Jennifer E. Liu, Marcello Chin&, Dawn Fishman, Jonathan N. Bella, 
James Galloway, Elisa T. Lee, Lyle Best, Richard B. Devereux, Weill Medical College of 
Cornell University, New York, NY 
Background: Relations of left ventricular (LV) diastolic filling patterns to hypertension and 
overweight have been extensively examined in cross-sectional studies but there are few 
data on long-term evolution of LV filling parameters in population-based samples. 
Methods: LV filling parameters were measured by Doppler echocardiography 7.2kO.7 
years apart in 247 American Indian participants (69% women, 58~7 years of age at base- 
line evaluation) in the population-based Strong Heart Study. 
Results: Between examtnations, there were no significant changes rn the systolic blood 
pressure (from 135+16 to 137*19mmHg, NS) and body mass index (both=32*6 kg/m’, 
NS). LV mass increased from 153e.36 to 168*36 g with decreases in LV fractional shorl- 
ening (35+5 to 33+ 6%, both p<OOOi) and LV midwall shortening (17.6Q.3 to 
17.1&3%, p=O.OOl). In parallel, there were decreases ln the peak E wave velocity 
(59-tl6 to 50+13 cm/?@ peak A wave velocity (71+16 to 66+14 cm/set) and the E/A 
ratio of transmttral flow (0.87+0.27 to 0.76r0.21, all pcO.001) accompanied by an 
increased prevalence of E/A ratio below a prognostically-validated partition value of 0.60 
(14 6% to 17.4%, p<O.O2). The decline between examinations in the mitral E/A ratio was 
related to older age at baseline evaluation (r=0.19, p=O.O02) and lesser decrease in ejec- 
bon fraction (r=-0.18, p=O.O07) but not to gender or change in body mass Index or sys- 
tollc pressure. In multiple regression analysis, the decline in mitral E/A ratio was greater 
with higher initial age (p=O.Ol) and less with decline in LV ejection fraction (p=O.O26) but 
was unrelated to temporal change in arterial pressure, LV mass, or body mass index. 
Conclusions: In a population-based sample of mtddle-aged and elderly adults, a 7-year 
follow-up of LV filling pattern among 247 American Indians participants showed that 
there was significant increase in the prevalence of transmitral E/A ratio below a prognos- 
tically-validated partition value. The decline between examinations in the mitral E/A ratio 
was related to older age at baseline evaluation and less with decline in ejection fraction 
and was unrelated to temporal change in arterial pressure, gender difference, LV mass, 
or body mass index 
1136-82 Evidence of Impaired Left Atrial Function Response to 
Exercise in Hypertrophic Cardiomyopathy Patients With 
Heart Failure 
Cinzia Cianfrocca, Francesco Pelliccia. Antonio Auriti, Furio Colivicchi, Antonino 
Granatelli, Giuseppe Richichi. Massimo Santlni. San Filippo Neri Hospital, Rome, Italy 
Background: Studies on determinants of symptoms of heart failure (HF) in pts with 
hypertrophic cardiomyopathy (HC) have focused mainly on LV systolic and/or diastolic 
dysfunction, whereas the pathophysiologic role of left atnal (LA) dynamics has been 
poorly investigated. To address this issue, we investigated the LA systolic function at rest 
and on exercise in a subset of HC pts with mild HF. 
Methods: Fifteen HC pts in NYHA class II (Gr.A; age: 47211 yrs) and 15 sax- and age- 
matched HC pts without symptoms of HF (Gr.6; age: 49_+12 yrs) were studied. All pts 
underwent, off-drug, a symptom-limited supine bicycle exercise test (25 watt/P mins). 
Doppler echocardiography was performed at baseline and at peak exercise. Indexes of 
LA morphology and function were derived from the apical 4. and P-chamber wws. 
Results: At baseline, the 2 groups exhibited similar LV morphology (i.e. maximal wall 
thickness and diameters), LV ejection fraction (55111 vs 63+9%, NS), and Doppler mea- 
sures of LV diastolic performance, i.e. E-peak (45217 vs 49119 cm/s, NS) and A-peak 
(66216 vs 61215 cm/s, NS). Also, they had similar LA maximal volume (7317 vs 71221 
cm3). LA stroke volume (11+8 vs 12+8 cd), and LA emptying fra& (l&9 vs 
25+10%). Exercise time was 441+220 s in Gr.A and 56e297 s in Gr.B. On exercise, LV 
ejection fraction did not change in Gr.A (-al 0%) but increased in Gr.B (+I &lo%, 
p<O.O5). No significant change with exercise in LA stroke volume (++6 ems) and LA 
emptying fraction (+&6) were seen in Gr.A. On the opposite, Gr.B showed an increase 
with exercise in LA stroke volume (+&8 ems, p&01), and LA emptying fraction 
(+15+10%, p<O.Ol). Comparison of Doppler indexes of LV filling in Gr.A showed no 
change with exercise in E-peak (-7~10 cm/s) and A-peak (+a10 cm/s). In Gr.B, con- 
versely, there were on exercise a slight increase in E-peak (+I9215 cm/s) and a signifi- 
cant augmentation in A-peak (+35+19 cm/s, p<O.Ol). 
Conclusion: Along with LV dynazc abnormalities, an impalred LA function response to 
exercise plays a pathophysiologic role in determining symptoms of mild HF in HC. These 
findings provide evidence that the LA myocardium is involved by the myopathic process 
in a subset of pts with HC. 
1136-83 100 Patients Supported for Over One Year on an 
Implanted Left Ventricular Assist Device 
R. Hetzer. R. Koerfer, M. Vigano, M. Pasque, R. Kormos, P. Partner, Tofv Mussivand on 
behalf of the Novacor LVAS Investigators, University of Ottawa Heart Institute. Ottawa, 
ON, Canada 
Background: The use of mechanical circulatory support (MCS) devices during the 
bridge to transplant experience can provide clinical insight into the potential use of these 
devices for long-term support or “Destination Therapy”. A review of the outcomes of first 
100 end-stage heart failure patients supported for greater than 1 year with an implanted 
left ventricular assist device (Novacor LVAS) was conducted. Methods: Utilizing data 
from the international registry, the patient characteristics and outcomes of 100 patients 
supported for > 1 year at 40 international centres were analyzed. Results: The patients 
ware 90% male with a mean age of 47 years (16-72 years). The disease etiology was 
cardiomyopathy in 63%, ischemic heart disease in 26% and other in 10%. The Intent to 
treat was as follows: 92% as a bridge to transplant. 4% as a bridge to recovery (Europe) 
and 4% as an alternative to transplant. Mean support duration on the device was 1.7 
years (370-1514 days) and 22 patients were supported over 2 years, 8 ovar 3 years and 
3 over 4 years. Outcomes were favorable (either ongoing, transplanted or weaned) for 
78% of patients. Subsequent analysis of patients supported over 6 months and I, 2, & 3 
years respectively, yielded similar outcomes at each time interval. There were no deaths 
related to device failure and the majority of patients were able to return home to near nor- 
mal activities.Conclusions: 1) A significant majority (78%) of these end-stage heart fail- 
ure patients had favorable outcomes and extension of life. 2) Improved quality of life was 
demonstrated with the majority of patients discharged from hospital. 3) Overall device 
safety has been demonstrated with no patient deaths due to device failure, and 4) Long- 
tern dewce durability has been demonstrated with patients supported for over 4 years on 
a single devce. These findings provide clear evidence that mechanical circulatory sup- 
port could potentially provide substantial clinical benefits during long-term support or 
“Destination Therapy”. 
* Due to space limitations only investigators with more than 5 patients supported over 1 
year are listed. 
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1137-62 Expanding the Donor Pool: Acceptable Recipient 
Outcomes With the Use of Hearts From Donors With 
Hepatitis B Core Antibody Positivity or Intracranial 
Tumors 
Sean P. Pinney Faisal H. Cheema, Kim Marie Hammond, Jonathan Chen, Niloo M. 
Edwards, Donna Mancini, Columbia University, New York, NY 
Background: The shortage of avallable donors limits cardiac transplantation. Transplan- 
tation of hearts from marginal donors could expand the donor pool if accompanied by 
good recipient outcomes. Donor hearts from patients with hepatitis B core antibodies 
(HBcAb) have not been used due to concern about virus transmission. Similarly, donors 
with malignant brain tumors have also been excluded. We conducted a retrospective 
review to determine the success of transplanting hearts from donors who were HBcAb+ 
or had an Intracranial tumor. Methods: We reviewed donor and recipient charts for 
patients transplanted at our center between January 1. 1997 and September I, 2002. 
Results: Of 514 hearl transplants performed in this time period, 46 (8.9%) used hearts 
from these marginal donors Fourteen patients (age 56+11 years) received hearts from 
donors with an intracranial tumor (age 4Ot9.6 years) Including 6 glioblastoma multiforme, 
2 anaplastic astrocytoma, 1 astrocytoma, 1 medulloblastoma. 1 pineal tumor. 1 meningi- 
oma and 2 not specified. At 23*10 months of follow-up, no patient had clinical or radio- 
logic evidence of tumor transmission. Thirty-two patients (age 46.9+18.7 years) received 
heatis from HBcAb+ donors (age 37.5*11 .O years). One patient (baseline HBSAg-) 
developed donor-transmitted HBV infection 10 months post-transplant that was success- 
fully treated with lamivudine. Two patients (baseline HBSAb-) had HBV seroconversion 
(HBSAb+) without evidence of HBV infection. Six patients were HBSAb+ pre-transplant 
and four patients (HBSAb-) received prophylactic lamivudine post-transplant. None of 
these patients developed donor-transmitted hepatitis; one lamivudine-treated patient 
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developed HBV seroconversion. Overall, suwival in this small cohort was no different 
than that for all patients transplanted at our center during this time period. Conclusion: 
Transplantation of hearts from HBcAb+ donors is associated with a low HBV transmis- 
sion risk. Transplantation of hearts from donors with intracranial tumors is not associated 
with tumor transmission. Use of hearts from these marginal donors should be considered 
safe and may help to augment the available donor pool. 
1137-63 Recent Outcomes in Cardiac Transplant Patients 
Receiving Hepatitis C Allografts: A Single Center 
Experience 
Jaymica P. Patel, Jianesh K. Patel, Brandy T. Cole, Maria Espejo Vassilakis, Lynda 
Kessler, Bernard Kubak, Jon A. Kobashigawa. The David Geffen School of Medicine at 
UCLA, Los Angeles, CA 
Background: Hepatitis C infection in the non-immunocompromised population is a 
chronic progressive disease with clinical manifestations after several years, The long- 
term impact of hepatitis C following heart transplantation remains unclear. 
Methods: Medical records pertaining to heart transplant recipients receiving allografts 
from hepatitis C positive donors between August 1991 and August 2002 were reviewed 
retrospectively. 23 patients were identified as having received allografts from hepatitis C 
positive donors. Df these, 7 recipients were hepatitis C positive prior to transplantation 
and 9 patients were Status I listing. Overall survival was determined. The presence of 
diabetes mellitus, hypertension, renal function, post-transplant albumin, donor age, pra- 
transplant hepatitis C status and type of immunosuppression used were determined to 
assess possible contribution to outcomes. 
Results: Overall survival in patients receiving hepatitis C positive allografts was 57% at 
one year and 17% at 5 years. This compared to an overall one-year survival of 62% at 
one year and 70% at 5 years for all adult heart transplants. Cause of death was due to 
multisystem organ failure and/or sepsis (5) liver failure (2) transplant coronary disease 
(2) unexplained sudden death (2). malignancy (2) rejection (1) and pulmonary embolus 
(I). By multivariate analysis and logistic regression, the only significant predictor for mor- 
tality was low post-transplant albumin (p<O.O17). Pre-transplant hepatitis C status or type 
of immunosuppression used did not significantly affect outcome. 
Conclusion: Patients receiving hepatitis C positive cardiac aflografts have a significantly 
worse outcome when compared to the outcome for all adult heart transplants in our insti- 
tution. Their mortality compares to patients with severe heart failure. These data suggest 
that the use of cardiac allografts from hepatitis C positive donors should be restricted to 
critically ill patients awaiting transplantation for whom other treatment modalities are 
unsuitable. 
1137-64 The Vagrancy of B-Type Natriuretic Peptide Levels in 
Heart Transplant Recipients Receiving Tacrolimus 
Daniel Crua Maria Espejo Vassilakis, Jignesh K. P&l, Alan Garfinkel, Gregg Fonarow, 
Jaime Moriguchi, Jon A. Kobashigawa, The David Geffen School of Medicine at UCLA, 
Los Angeles, CA 
Background: Tacrolimus (FK506) is a potent immunosuppressant often used in place of 
cyclosporine (CSA) in heart transplant (HT) patients. Prior studies on HT patients on 
CSA have demonstrated that B-type natriuretic peptrde (BNP) levels are elevated and 
even continue to rise after HT. However, studies utilizing BNP as a marker of filling pres- 
sures and rejection have been discordant. It is unknown if the same BNP patterns exist 
for HT recipients receiving FK506. Methods: We retrospectively analyzed BNP levels I” 
49 patients on CSA or FK506 who were transplanted between August 2001 and May 
2002. 300 BNP levels were drawn at the time that hemodynamic measurements and 
ventricular biopsies were performed. Mean follow-up was 5.6 months. Recipients with 
end-stage renal disease and those followed by outside institutions were excluded. 
Results: Most patients receiving FK506 normalize BNP levels (slope -40.2, p<O.OOOl). 
26/33 patients (76%) reached BNP levels of <IO0 pg/ml by 4 months. Both the CSA and 
FK506 groups had similar ejectton fraction, pulmonary capillary wedge (PCW) pressure, 
and creatinine. In FK506 recipients, a weak correlation coefficient (r = 0.4) was observed 
between PCW and BNP. Utilizing a BNP level of 150 pglml and PCW of 14 mmHg, the 
sensitivity of the assay decreased from 100% during the first two months to 21% during 
the subsequent months. In contrast, the specificity of the assay increased from 34% to 
61% during the same time period. There were 7 episodes of rejection (3 cellular and 3 
humoral) in 6 HT recipients. Cases were not preceded by an increase in BNP in the days 
to weeks prior to presentation. Conclusions: Most patients on FK506 achieve normal 
BNP levels by 4 months in contrast to those reported HT patients on CSA. In HT patients 
on FK506, BNP appears to be an inadequate assay to screen for rejection or volume sta- 
tus. The mechanism by which FK506 suppresses BNP levels after OHT deserves further 
investigation. 
1137-65 Effects of Growth Hormone Therapy Following Pediatric 
Cardiac Transplantation 
Seema Mital, Aleza Andron, Barney Softness, Daphne T. Hsu, Jacque M. Lamour. Linda 
J. Addonizio, Columbia University, New York, NY 
Background: Growth hormone (GH) is used to treat growth failure following cardiac trans- 
plantation (TX). GH can increase cardiac muscle mass and improve function in patients 
with cardiomyopathy. We evaluated the safety, efficacy and cardiac effects of GH in chil- 
dren following cardiac TX. 
Methods: Ten pediatric cardiac TX recipients with growth failure were followed serially for 
4 years before and after GH therapy. Parameters followed included growth velocity (GV), 
cyclosporine levels, frequency of rejection episodes, echocardiographic measures of car- 
diac function and dimensions, and hemodynamic measurements. To determine if out- 
comes were related to increased GV or to a direct effect of GH, these data were 
compared to measurements obtained in 6 age-matched pediatric cardiac TX recipients 
experiencing a natural growth spurt. Results: The mean age at TX in the GH group was 
7.6*1 yr with mean age at onset of GH therapy of 13*1 yr (mean duration, 2.5+1 yr). The 
mean GV increased following GH and was not different from controls (8.6*1 vs 7.1*1 
cmJyr). Cyclosporine levels were maintained during the growth spurt (312+34 vs 266+26 
ng/ml). The frequency of rejection episodes was not different in GH group compared to 
controls (0.1+0.2/yr vs 0.4*0.3/y& LV shortening fraction increased in GH group from 
36*2% to 44*2%, (~~0.05) and was higher compared to controls (37+2%. p<O.O5). The 
SF returned to baseline levels after discontinuation of GH. Cardiac index increased fol- 
lowing GH (3.2*0.3% to 3.9+0.2%, p=O.Ol) and was higher than controls (2.9*0.3%, 
pcO.01). Mixed venous saturations were higher following GH (76*1% to 7li2%, p<O.O5). 
The calculated LV mass increased from 95+11 g/m2 to 117+17 g/m2 following GH 
(p=O.Ol) and was higher than controls (95+7 g/m2, p<O.O5). LV mass/volume ratio was 
also higher in GH group (0.72+0.02) compared to controls (0.67iO.03, p=O.O5). Conclu- 
sion: GH IS a safe and effective therapy for growth failure in children following cardiac TX 
even in the absence of GH deficiency. GH therapy is also associated with short-term 
improvement in ventricular mass, cardiac function and hemodynamics. Whether these 
beneficial effects are sustained in the long term remains to be determined. 
1137-66 Survival Pre and Post-Heart Transplantation in Patients 
Listed as UNOS Status 2: Do UNOS Status 2 Patients 
Benefit From Transplantation? 
Javier Jimenez, Leah Bennett Edwards, Robert Higgins, Joseph Bauerlein, Si Pham, 
Stephen Mallon, Jackson Memorial Medical Center, Miami, FL, United Network for Organ 
Sharing, Richmond, VA 
Introduction: Improved outcomes with contemporary medical therapy in patients with 
advanced heart failure questions the benefit of transplantation (TX) in UNOS status 2 
patients. 
Methods: Between January 1999 and June 2001; 4,255 patients were listed for heart TX 
as UNOS status 2. Using a competing risk method, probabilities of events on the waiting 
list were computed. Additionally, a time dependent proportional hazards model was used 
to determine predictors of death pre and post TX. 
Results: Demographics of this cohort revealed a mean age of 52.3 years, female gender 
(23%) ischemic etiology (46%) diabetes (21%) white race (65%) and mean time on the 
waiting list (396.5 days). Relative risks of death (> 1 indicates an increased risk) com- 
pared to patients remaining on the waiting list as status 2 were: upgrade to status 1 A; RR 
14.9 (95%CI 9.7-22.2) upgrade to status 1 B; RR 3.4 (95%CI 2.4-4.7). O-7 days following 
TX as status 2; RR 16.7 (95%CI 9.3-30.2) and 7-33 days following TX as status 2; RR 
6.5 (95%CI 3.7-l 1.2). All factor were significant at p<O.OOOl. The overall relative risk of 
death following TX (365+ days) for status 2 patients initially listed as status 2 compared 
to those that continue to wait as status 2 is shown below; RR 0.92 (95%CI 0.5-I .56, 
p=O.6). 
Conclusion: After accounting for early perioperative mortality, there appears to be little 
suwival benefit at one year in transplantrng UNOS status 2 patients. The point of optimal 
benefit from TX in UNOS status 2 patients may need to be funther defined. 
1137-67 Cytomegalovirus Infection Negatively Influences 
Coronary Remodeling Modalities in Heart Transplant 
Recipients: A Prospective Study 
Luciano Potena. Francesco Grigioni, Fabio Coccolo. Gaia Magnani, Paolo Ortolanr, 
Cinzia Marrozzini. Antonio Marzocchi. Simona Sorbello. Anna C. Musuraca, Carlo 
Magelli, Angelo Branzi, University of Bologna, Bologna, Italy 
Background. Graft coronary disease (GVD) is a major determinant of mortality after 
heart transplantation (HT). This peculiar form of atherosclerosis has been recently identi- 
fied as the result of the interaction between intimal hyperplasia and vessel wall response 
(i.e. vascular remodeling). Although immunological and traditional risk factors an? known 
to be implied in GVD pathogenesis, their contribution to remodeling process remains 
undetermined. 
Methods. 37 consecutive HT recipients were prospectively studied (age 52illyrs; 75% 
males; donor age 32il lyrs). lntracoronary ultrasound (IVUS) of proximal-mid left ante- 
rior descending was performed at 1 and 12 months after HT. Vessel, lumen and intimal 
volume changes over this period were analyzed. 
Results. 1169 IVUS images were obtained. Overall intimal volume increased (+60%. 
PcO.001) while vessel volume remained unchanged (P=O.2) and thus, lumen volume 
decreased (-9%, P=O.Ol). Among all the clinical and demographic characteristics ana- 
lyzed (e.g. donor features, immunosuppression, lipid panel, biopsy score), only the 
occurrence of cytomegalovirus (CMV) infection was associated with coronary lumen loss 
(P=O.O47). Patients who presented CMV infection (11~14) showed an higher increase in 
intimal volume (I 16% vs. 59%, P=O.O7), but not in vessel volume (+I% vs. +4%, P=O.5). 
Therefore, CMV infected patients showed a more significant lumen loss (-13% vs -3%, 
P=O.O4). A trend towards an association between LDL and intimal growth was present 
only in CMV infected recipients (R=0.46, P=O.O7). 
Conclusions. This prospective study suggests for the first time that occurrence of CMV 
infection during the first post-HT year negatively affects vascular remodeling, ultimately 
resulting in coronary lumen loss. LDL serum levels might contribute to lumen loss inter- 
acting with CMV infection in stimulating intimal growth. 
